Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Ralph Chebib; Loic Verlingue; Nathalie Cozic; Matthieu Faron; Pascal Burtin; Valérie Boige; Antoine Hollebecque; David Malka

doi:10.1053/j.seminoncol.2017.07.004

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Semin Oncol. 2017 Apr;44(2):114-128. doi: 10.1053/j.seminoncol.2017.07.004. Epub 2017 Aug 2.

Authors

Ralph Chebib¹, Loic Verlingue¹, Nathalie Cozic², Matthieu Faron³, Pascal Burtin¹, Valérie Boige¹, Antoine Hollebecque⁴, David Malka⁵

Affiliations

¹ Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Paris, France.
² Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, Paris, France; INSERM U1018, CESP, Gustave Roussy, Université Paris-Saclay, Paris, France; Ligue Nationale Contre le Cancer Meta-Analysis Platform, Gustave Roussy, Université Paris-Saclay, Paris France.
³ Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, Paris, France; INSERM U1018, CESP, Gustave Roussy, Université Paris-Saclay, Paris, France; Département de Chirurgie Digestive, Gustave Roussy, Université Paris-Saclay, Paris, France.
⁴ Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Paris, France; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Villejuif, France.
⁵ Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Paris, France. Electronic address: david.malka@gustaveroussy.fr.

PMID: 28923209
DOI: 10.1053/j.seminoncol.2017.07.004

Abstract

The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.

Keywords: Angiogenesis inhibitors; Colorectal cancer; Pooled analysis; Second-line chemotherapy; Systematic review.

Publication types

Review
Systematic Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab / therapeutic use*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology
ErbB Receptors / antagonists & inhibitors*
Humans
Neoplasm Metastasis
Neovascularization, Pathologic / prevention & control*
Phenylurea Compounds / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Pyridines / therapeutic use
Ramucirumab
Receptors, Vascular Endothelial Growth Factor / therapeutic use
Recombinant Fusion Proteins / therapeutic use
Retreatment

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Phenylurea Compounds
Protein Kinase Inhibitors
Pyridines
Recombinant Fusion Proteins
aflibercept
regorafenib
Bevacizumab
ErbB Receptors
Receptors, Vascular Endothelial Growth Factor